Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011)

Diagnostic Microbiology and Infectious Disease

Volumn 78, Issue 4, 2014, Pages 422-428

  Pfaller, Michael A ^a   Flamm, Robert K ^a   Sader, Helio S ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Anti MRSA cephalosporins; MRSA; Staphylococcus aureus

Indexed keywords

CEFEPIME; CEFTAROLINE; CEFTAZIDIME; CEFTRIAXONE; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIGECYCLINE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BETA HEMOLYTIC STREPTOCOCCUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; ESCHERICHIA COLI; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; WILD TYPE;

ANTI-MRSA CEPHALOSPORINS; MRSA; STAPHYLOCOCCUS AUREUS;

ACADEMIC MEDICAL CENTERS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; UNITED STATES;

EID: 84895864880     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.08.027     Document Type: Article

References (15)

1. Biek D., Critchley I.A., Riccobene T.A., Thye D.A. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity. J Antimicrob Chemother 2010, 65(Suppl 4):iv9-iv16.
2. Castanheira M., Farrell S.E., Deshpande L.M., Mendes R.E., Jones R.N. Prevalence of β-lactamase encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 USA hospitals: Report from the SENTRY Antimicrobial Surveillance Program (2010). Antimicrob Agents Chemother 2013, 57:3012-3020.
3. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 2012, CLSI, Wayne, PA. ninth edition, M07-A9.
4. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 23rd informational supplement 2013, CLSI, Wayne, PA. (M100-S23).
5. Dryden M.S. Complicated skin and soft tissue infection. J Antimicrob Chemother 2010, 65(Suppl 3):iii35-iii44.
6. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0, January 2013. Available at. Accessed January 2, 2013. http://www.eucast.org/clinical_breakpoints/.
7. Flamm R.K., Sader H.S., Farrell D.J., Jones R.N. Summary of ceftaroline activity against pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program. Antimicrob Agents Chemother 2012, 56:2933-2940.
8. Friedland H.D., O'Neal T., Biek D., Eckburg P.B., Rank D.R., Llorens L., et al. CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2012, 56:2231-2236.
9. Kaiser R.M., Castanheira M., Jones R.N., Tenover F., Lynfield R. Trends in Klebsiella pneumoniae carbapenemase-positive K. pneumoniae in US hospitals: Report from the 2007-2009 SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2013, 76:356-360.
10. MacGowan A.P., Noel A.R., Tomaselli S., Bowker K.E. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother 2013, 57:2451-2456.
11. Sader H.S., Flamm R.K., Jones R.N. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010). Diagn Microbiol Infect Dis 2013, 76:61-68.
12. Saravolatz L.D., Stein G.E., Johnson L.B. Ceftaroline: A novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2011, 52:1156-1163.
13. Stevens D.L., Bisno A.L., Chambers H.F., Everett E.D., Dellinger P., Goldstein E.J., et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005, 41:1373-1406.
14. Teflaro® Package Insert 2012. New York City, NY. Available at. Accessed August 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/200327s009lbl.pdf.
15. Zinforo™ Package Insert Prescribing Information Available at, Accessed January 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002252/WC500132586.pdf.